Table 2 Treatment regimens and antiviral response
Regimen | All patients (N = 147) | Patients who were evaluated for SVR (N = 132) | Patients with treatment discontinuation or loss to follow-up (N = 15) | Virologic responses | |||
|---|---|---|---|---|---|---|---|
RVR (N = 109) | SVR (N = 132) | ||||||
Rate (%) | 95% CI of %* | Rate (%) | 95% CI of %* | ||||
SOF/LDV 12 W | 32 (21.8%) | 30 (22.7%) | 2 (13.3%) | 15/16 (93.8%) | 69.8–99.8% | 30/30 (100%) | 88.4–100% |
SOF/LDV 24 W | 9 (6.1%) | 7 (5.3%) | 2 (13.3%) | 9/9 (100%) | 66.4–100% | 7/7 (100%) | 59.0–100% |
SOF/LDV + RBV 12 W | 46 (31.3%) | 42 (31.8%) | 4 (26.6%) | 39/41 (95.1%) | 83.5–99.4% | 42/42 (100%) | 91.6–100% |
SOF/LDV + RBV 24 W | 7 (4.8%) | 6 (4.5%) | 1 (6.7%) | 3/6 (50%) | 11.8–88.2% | 6/6 (100%) | 54.1–100% |
SOF/DCV 12 W | 22 (15%) | 20 (15.1%) | 2 (13.3%) | 14/14 (100%) | 76.9–100% | 20/20 (100%) | 83.2–100% |
SOF/DCV 24 W | 4 (2.7%) | 3 (2.3%) | 1 (6.7%) | 2/2 (100%) | 15.8–100% | 3/3 (100%) | 29.2–100% |
SOF/DCV + RBV 12 W | 5 (3.4%) | 4 (3.1%) | 1 (6.7%) | 3/3 (100%) | 29.2–100% | 4/4 (100%) | 39.8–100% |
SOF/DCV + RBV 24 W | 13 (8.8%) | 12 (9.1%) | 1 (6.7%) | 13/13 (100%) | 75.3–100% | 12/12 (100%) | 73.5–100% |
SOF/VEL 12 W | 7 (4.7%) | 7 (5.3%) | 0 (0%) | 4/4 (100%) | 39.8–100% | 7/7 (100%) | 59.0–100% |
SOF/VEL 24 W | 1 (0.7%) | 0 (0%) | 1 (6.7%) | NA | NA | NA | NA |
SOF + RBV 24 W | 1 (0.7%) | 1 (0.8%) | 0 (0%) | 1/1 (100%) | 2.5–100% | 1/1 (100%) | 2.5–100% |
Total | 147 (100%) | 132 (100%) | 15 (100%) | 103/109 (94.5%) | 88.4–98.0% | 132/132 (100%) | 97.2–100% |